The primary objective of this study is to demonstrate superior efficacy of a combination of ticagrelor and RIPC in the reduction of PMI compared to a clopidogrel-RIPC combination or ticagrelor alone by evaluating post-procedural cardiac Troponin I cTnI levels defined as cTnI at 24 hours post-PCI
Data and Resources
- Ticagrelor Potentiation of Remote Ischemic Preconditioning: The Ticagrelor in Remote Ischemic Preconditioning TRIP studyjson
The primary objective of this study is to demonstrate superior efficacy of a...
|Release Date|| |
|Public Access Level|| |